Cargando…

Fibronectin Functions as a Selective Agonist for Distinct Toll-like Receptors in Triple-Negative Breast Cancer

The microenvironment of tumors is characterized by structural changes in the fibronectin matrix, which include increased deposition of the EDA isoform of fibronectin and the unfolding of the fibronectin Type III domains. The impact of these structural changes on tumor progression is not well underst...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ambesi, Anthony, Maddali, Pranav, McKeown-Longo, Paula J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9265717/ https://www.ncbi.nlm.nih.gov/pubmed/35805158 http://dx.doi.org/10.3390/cells11132074

Ejemplares similares

Induction of pro-inflammatory genes by fibronectin DAMPs in three fibroblast cell lines: Role of TAK1 and MAP kinases
por: Maddali, Pranav, et al.
Publicado: (2023)

Role of TLR4 Receptor Complex in the Regulation of the Innate Immune Response by Fibronectin
por: Zheng, Mingzhe, et al.
Publicado: (2020)

Endostatin and anastellin inhibit distinct aspects of the angiogenic process
por: Neskey, David M, et al.
Publicado: (2008)

Activation of Distinct α(5)β(1)-mediated Signaling Pathways by Fibronectin's Cell Adhesion and Matrix Assembly Domains
por: Hocking, Denise C., et al.
Publicado: (1998)

Coordinate regulation of fibronectin matrix assembly by the plasminogen activator system and vitronectin in human osteosarcoma cells
por: Vial, Daniel, et al.
Publicado: (2006)

Regulation of the Innate Immune Response by Fibronectin: Synergism between the III-1 and EDA Domains
por: Kelsh, Rhiannon, et al.
Publicado: (2014)

The First Type III Domain of Fibronectin is Associated with the Expression of Cytokines within the Lung Tumor Microenvironment
por: Zheng, Mingzhe, et al.
Publicado: (2011)

Fibronectin in the Tumor Microenvironment Activates a TLR4-dependent Inflammatory Response in Lung Cancer Cells
por: Cho, Christina, et al.
Publicado: (2020)

The fibronectin III-1 domain activates a PI3-Kinase/Akt signaling pathway leading to αvβ5 integrin activation and TRAIL resistance in human lung cancer cells
por: Cho, Christina, et al.
Publicado: (2016)

Toll-Like Receptor 9 Agonists in Cancer
por: Karapetyan, Lilit, et al.
Publicado: (2020)

Toll-Like Receptor 9 Agonists for Cancer Therapy
por: Melisi, Davide, et al.
Publicado: (2014)

Toll-Like Receptor Agonists as Adjuvants for Allergen Immunotherapy
por: Kirtland, Max E., et al.
Publicado: (2020)

The Mycobacterium avium subsp. paratuberculosis fibronectin attachment protein, a toll-like receptor 4 agonist, enhances dendritic cell-based cancer vaccine potency
por: Noh, Kyung Tae, et al.
Publicado: (2012)

The Toll-Like Receptor Agonist Imiquimod Is Active against Prions
por: Oumata, Nassima, et al.
Publicado: (2013)

Trial Watch: Toll-like receptor agonists for cancer therapy
por: Vacchelli, Erika, et al.
Publicado: (2013)

Trial Watch: Toll-like receptor agonists in oncological indications
por: Aranda, Fernando, et al.
Publicado: (2014)

Anti-tumor Activity of Toll-Like Receptor 7 Agonists
por: Chi, Huju, et al.
Publicado: (2017)

The Role of Toll-like Receptor Agonists and Their Nanomedicines for Tumor Immunotherapy
por: Huang, Lingling, et al.
Publicado: (2022)

Applications and clinical trial landscape using Toll-like receptor agonists to reduce the toll of cancer
por: Rolfo, Christian, et al.
Publicado: (2023)

Impact of Selected Bacterial and Viral Toll-like Receptor Agonists on the Phenotype and Function of Camel Blood Neutrophils
por: Hussen, Jamal, et al.
Publicado: (2023)

Synthesis and Immunological Characterization of Toll-Like Receptor 7 Agonistic Conjugates
por: Chan, Michael, et al.
Publicado: (2009)

Toll-like receptor 2 agonists inhibit human fibrocyte differentiation
por: Maharjan, Anu S, et al.
Publicado: (2010)

Trial Watch: Experimental Toll-like receptor agonists for cancer therapy
por: Galluzzi, Lorenzo, et al.
Publicado: (2012)

The Use of Toll-Like Receptor Agonists in HIV-1 Cure Strategies
por: Martinsen, Janne Tegder, et al.
Publicado: (2020)

Targeting Cellular and Tissue HIV Reservoirs With Toll-Like Receptor Agonists
por: Macedo, Amanda B., et al.
Publicado: (2019)

Bibliometric analysis of toll-like receptor agonists associated with cancer therapy
por: Li, Wei, et al.
Publicado: (2022)

Toll-like receptor (TLRs) agonists and antagonists for COVID-19 treatments
por: Liu, Zhi-Mei, et al.
Publicado: (2022)

Application of toll-like receptors (TLRs) and their agonists in cancer vaccines and immunotherapy
por: Chakraborty, Samik, et al.
Publicado: (2023)

The Toll‐like receptor 7 agonist imiquimod increases ethanol self‐administration and induces expression of Toll‐like receptor related genes
por: Lovelock, Dennis F., et al.
Publicado: (2022)

Differential modulation of cysteinyl leukotriene receptor 1 and 2 expression by distinct Toll-like receptor agonists in monocyte-derived dendritic cells
por: Rola-Pleszczynski, M, et al.
Publicado: (2004)

Cellular Fibronectin Containing Extra Domain A Causes Insulin Resistance via Toll-like Receptor 4
por: Rajak, Sangam, et al.
Publicado: (2020)

Instrumentation for negative ion detection.
por: McKeown, M
Publicado: (1980)

Systemic cancer immunotherapy with Toll-like receptor 7 agonists: Timing is everything
por: Hotz, Christian, et al.
Publicado: (2012)

Use of Toll-Like Receptor 3 Agonists Against Respiratory Viral Infections
por: Christopher, ME, et al.
Publicado: (2011)

Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy
por: Vacchelli, Erika, et al.
Publicado: (2012)

Natural toll-like receptor agonists in prophylactic vaccines for dendritic cell activation
por: Peng, Paul, et al.
Publicado: (2015)

The functional and inflammatory response of brain endothelial cells to Toll-Like Receptor agonists
por: Johnson, Rebecca H., et al.
Publicado: (2018)

Toll-Like Receptor Agonists Modulate Wound Regeneration in Airway Epithelial Cells
por: Lewandowska-Polak, Anna, et al.
Publicado: (2018)

Toll-like receptor 2 agonist exacerbates renal injury in diabetic mice
por: Li, Fanglin, et al.
Publicado: (2017)

Innate and Adaptive Responses of Intratumoral Immunotherapy with Endosomal Toll-Like Receptor Agonists
por: Andón, Fernando Torres, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0m079n6bqrnudun14fshhffu8p